Drug Trial Radar · NCT07214727
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 15, 2025
Primary completion
Mar 6, 2030
Study completion Mar 6, 2030
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
Conditions
- Alzheimer's Disease
Interventions
ALN-5288Drug
ALN-5288 will be administered IT.
PlaceboDrug
Placebo will be administered IT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs)Time frame: Up to 32 months
- Severity of AEsTime frame: Up to 32 months
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Montreal, Canada · Recruiting
Clinical Trial Site
Ottawa, Canada · Recruiting
Clinical Trial Site
Toronto, Canada · Recruiting
Clinical Trial Site
Toronto, Canada · Not yet recruiting
Clinical Trial Site
's-Hertogenbosch, Netherlands · Recruiting
Clinical Trial Site
Amsterdam, Netherlands · Recruiting
Clinical Trial Site
Barcelona, Spain · Not yet recruiting
Clinical Trial Site
Madrid, Spain · Recruiting
Clinical Trial Site
Sant Cugat del Vallès, Spain · Not yet recruiting
Clinical Trial Site
Glasgow, United Kingdom · Recruiting
Clinical Trial Site
London, United Kingdom · Recruiting
Clinical Trial Site
Sheffield, United Kingdom · Recruiting
Clinical Trial Site
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.